Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 10/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.37 |
| ▸ | QPCT | Q16769 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22440192 | 0.80 | DHFR (0.51) | QPCTPDGFRB | |
| SCHEMBL21303625 | 0.79 | CLK1 (0.40) | CLK1DYRK1AQPCTABL1 | |
| SCHEMBL22440183 | 0.78 | QPCT (0.47) | QPCT | |
| SCHEMBL22440202 | 0.76 | NPC1 (0.43) | BRAFCLK1DYRK1AABL1DYRK1B | |
| SCHEMBL22440210 | 0.76 | LTA4H (0.52) | CLK1DYRK1ACLK2CLK4DYRK1B | |
| SCHEMBL22440191 | 0.76 | QPCT (0.49) | CLK1DYRK1AQPCTABL1AURKA | |
| SCHEMBL22440204 | 0.75 | CDC7 (0.56) | MAPK8 | |
| SCHEMBL22440207 | 0.75 | MAPT (0.53) | CLK1DYRK1AQPCTABL1GSK3A | |
| SCHEMBL21295263 | 0.75 | PIK3CA (0.38) | QPCTABL1 | |
| SCHEMBL30176758 | 0.71 | ALOX5AP (0.47) | BRAFQPCTALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-04-16 | — | — | US | disclosed |
| US-20200392174-A1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-3589632-B1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev (DE) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392174-A1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | GMPS, GLS, QPCT | BRAF 4227/4885CLK1 2815/4885DYRK1A 4411/4885 |
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | GMPS, GLS, QPCT | BRAF 4201/4885CLK1 2925/4885DYRK1A 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.